Alzheimer’s disease
The NIH revealed that bumetanide, a drug typically used as a diuretic, maybe a potential treatment for those genetically at risk for Alzheimer’s. Know more about it here.
Roche’s candidate drug for Alzheimer’s treatment received breakthrough therapy designation which has increased its chance of getting full FDA approval.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Cassava Sciences announced top-line results Wednesday from a 12-month interim analysis of its Alzheimer’s drug candidate simufilam.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
The Neurology Center posted a notice, saying, “At this time, the NCPA physicians will not be recommending this treatment for any of its patients.”
The growth of fibril tips is thought to be the ‘Achilles’ heel’ of the process.
Biogen CEO Michel Vounatsos admitted Thursday that the company’s rollout of Aduhelm (aducanumab) for Alzheimer’s disease has been “slower than we anticipated.”
Scientists from different agencies and research facilities have turned to laboratory manufactured human mini-brains to study the onset and progression of Parkinson’s disease.
The company sent the medication to a Florida neurology clinic free of charge.
PRESS RELEASES